AAN Corticosteroid Treatment Of Duchenne Muscular Dystrophy Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the American Academy of Neurology.

Document Overview

Document Title: Corticosteroid Treatment Of Duchenne Muscular Dystrophy

Authoring Society: American Academy of Neurology

Document Publication Date: Feb 1, 2016

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: n.neurology.org/content/86/5/465

Source Citation: David Gloss, et al. Corticosteroid Treatment Of Duchenne Muscular Dystrophy. Neurology. 2016; 86(5): 465-72.

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Scope: Assessment and Screening, Diagnosis, Management, Treatment

Keywords: deflazacort, duchene muscular dystrophy (DMD), prednisone

Inclusion Criteria: Male, Female, Adolescent, Adult, Child, Older Adult

Health Care Settings: Ambulatory, Emergency Care, Hospital, Outpatient

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resource: Data Supplement

Number of Source Documents: 40

Literature Search Start Date: Thursday, January 1, 2004

Literature Search End Date: Tuesday, July 1, 2014

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No